Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes
More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)
Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
06/2005
06/30/2005US20050142180 Comprises doses of Apolipoprotein A-I Milano:phospholipid complex to reduce and stabilize atherosclerotic plaque; for treating ischemic reperfusion
06/30/2005US20050142148 e.g. include antigenic gene product of another virus, such as influenza virus, respiratory syncytial virus, human metapneumovirus and avian pneumovirus; respiratory tract infections
06/30/2005US20050142139 and a histidine buffer; anti-HIV; higher concentrations, are storage stable, compatible with lyophilization, and safe to administer by intravenous injection
06/30/2005US20050142129 Methods of preventing morbidity and mortality by perioperative administration of a blood clotting inhibitor
06/30/2005US20050142106 Mutant interleukin-2 (IL-2) polypeptides
06/30/2005US20050142104 Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
06/30/2005US20050142071 Aerosol steroid solution formulation product with enhanced chemical resistance; container equipped with dispensing valve and having a corticosteroid of budesonide, triamcinolone acetonide, and/or rofleponide dissolved; internal surfaces coated with stainless steel, anodized aluminium or inert lining
06/30/2005CA2550695A1 Glp-1 pharmaceutical compositions
06/30/2005CA2550694A1 Quinoa protein concentrate, production and functionality
06/30/2005CA2550155A1 Hla-dr-specific antibodies, compositions and methods
06/30/2005CA2549800A1 Novel anti-dc-sign antibodies
06/30/2005CA2549001A1 Rifamycin analogs and uses thereof
06/30/2005CA2548502A1 Methods and compositions relating to ccr5 antagonist, ifn-.gamma. and il-13 induced inflammation
06/30/2005CA2548216A1 Methods of administering water-soluble prodrugs of propofol for extended sedation
06/29/2005EP1547603A2 Compositions and methods for use in targeting vascular destruction
06/29/2005EP1546733A2 Methods and compositions for modification of splicing of pre-mrna
06/29/2005EP1546408A2 A METHOD FOR GENERATION OF A RANDOM RNAi LIBRARY AND ITS APPLICATION IN CELL-BASED SCREENS
06/29/2005EP1546305A2 Implantable artificial organ devices
06/29/2005EP1546181A2 Methods of reducing ischemic injury
06/29/2005EP1546112A2 Imidazolopyridines and methods of making and using the same
06/29/2005EP1546099A2 3,6-disubstituted azabicyclo 3.1.0 hexane derivatives useful as muscarinic receptor antagonists
06/29/2005EP1545690A2 Selective plasma exchange therapy
06/29/2005EP1545634A2 Method of preparing dry powder inhalation compositions
06/29/2005EP1545625A2 Flexible vaccine assembly and vaccine delivery platform
06/29/2005EP1545597A2 Immunostimulatory compositions and methods of stimulating an immune response
06/29/2005EP1545596A2 Use of histamine h4 receptor modulators for the treatment of allergy and asthma
06/29/2005EP1545584A2 Method for reducing morbidity and mortality in critically ill patients
06/29/2005EP1545570A2 A composition for treating aids and associated conditions
06/29/2005EP1545502A2 Keto cannabinoids with therapeutic indications
06/29/2005EP1545407A2 Vaginal health products
06/29/2005EP1545211A1 Nodulisporic acid derivative spot-on formulations for combating parasites
06/29/2005EP1545209A2 Factors that bind intestinal toxins
06/29/2005EP1545206A2 Compositions and products containing enantiomeric equol, and methods for their making
06/29/2005EP1545204A2 Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
06/29/2005CN1633416A Nicotinamide derivates useful as p38 inhibitors
06/29/2005CN1633407A Carboxylic acid compounds for use as surfactants
06/29/2005CN1633306A Viral inhibition by n-docosanol
06/29/2005CN1208450C Method for the purification, recovery, and sporulation of cysts and oocysts
06/29/2005CN1208056C Medicine containing Anemonin as effective component for treating aseptic inflammation
06/28/2005US6911469 For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity
06/28/2005US6911217 Controlled release bead, a method of producing the same and multiple unit formulation comprising it
06/28/2005US6911211 Pharmaceutical and cosmetic carrier or composition for topical application
06/28/2005CA2402300C Fluorocarbon aerosol medicaments
06/28/2005CA2139771C A cosmetic fatty acid triglyceride composition
06/23/2005WO2005056075A2 Transdermal system for sustained delivery of polypeptides
06/23/2005WO2005056007A1 The use of urocanic acid being able to acidify the cell cytoplasm and for preventing or halting cellular proliferation in a person
06/23/2005WO2005055957A2 Influenza immunogen and vaccine
06/23/2005WO2005055956A2 Method for improving insulin sensitivity by administering an inhibitor of antitrypsin
06/23/2005WO2005055955A2 DOSING METHODS FOR ß-D-2’,3’-DIDEOXY-2’,3’-DIDEHYDRO-5-FLUOROCYTIDINE ANTIVIRAL THERAPY
06/23/2005WO2005055954A2 Pharmaceutical compounding systems and methods
06/23/2005WO2005055952A2 Synergistic anti-cancer compositions
06/23/2005WO2005055951A2 Methods and compositions for slowing aging
06/23/2005WO2005055950A2 Glycopegylated factor ix
06/23/2005WO2005055949A2 Sustained release preparations composed of biocompatible complex microparticles
06/23/2005WO2005055948A2 Epha2, epha4 and lmw-ptp and methods of treatment of hyperproliferative cell disorders
06/23/2005WO2005055947A2 Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions
06/23/2005WO2005055946A2 Glycopegylated granulocyte colony stimulating factor
06/23/2005WO2005055945A2 Mucoadhesive drug delivery devices and methods of making and using thereof
06/23/2005WO2005055944A2 Oligosaccharide compositions and use thereof in the treatment of infection
06/23/2005WO2005055943A2 Vinorelbine derivatives
06/23/2005WO2005055942A2 Modulation of brain pathways and function
06/23/2005WO2005055941A2 Novel m3 muscarinic acetylcholine receptor antagonists
06/23/2005WO2005055940A2 Novel m3 muscarinic acetylcholine receptor antagonists
06/23/2005WO2005055939A2 Vinca derivatives
06/23/2005WO2005055938A2 A low-weight ultra-thin flexible radiation attenuation composition
06/23/2005WO2005055937A2 Branched sulfates with improved odor properties and their use in personal care compositions
06/23/2005WO2005055936A2 Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
06/23/2005WO2005055935A2 Cationic substituted benzofurans as antimicrobial agents
06/23/2005WO2005055934A2 Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
06/23/2005WO2005055933A2 Treatment of psoriasis with rosiglitazone
06/23/2005WO2005055932A2 Therapeutic combinations and methods including irm compounds
06/23/2005WO2005055931A2 Method of preventing survival of retrovirally cells and of inhibiting formation of infectious retroviruses
06/23/2005WO2005055930A2 Recombinant factor viii having increased specific activity
06/23/2005WO2005055929A2 Methods and compositions for the treatment and management of hemoglobinopathy and anemia
06/23/2005WO2005055928A2 Zn2+ -chelating motif-tethered short -chain fatty acids as a novel class of histone deacetylase inhibitors
06/23/2005WO2005055926A2 Amelioration of cataracts, macular degeneration and other ophthalmic diseases
06/23/2005WO2005055925A2 14-3-3 zeta over-expression as a poor prognosis factor, and a therapeutic target in multiple cancer types
06/23/2005WO2005055924A2 Skin adherent hydrogels
06/23/2005WO2005055922A2 Use of benzothiopenes to treat and prevent prostate cancer
06/23/2005WO2005055921A2 Compositions for treatment of ear disorders and methods of use thereof
06/23/2005WO2005055920A2 Compositions and methods for treatment of psychiatric disorders
06/23/2005WO2005041888A3 Pyrimidin-4-one compounds, compositions and methods
06/23/2005WO2005041884A9 Polymer-based microstructures
06/23/2005WO2005039491A3 Certain improved combination bacteriolytic therapy for the treatment of tumors
06/23/2005WO2005037224A3 Muscarinic acetylcholine receptor antagonists
06/23/2005WO2005032485A3 Compounds and methods for the treatment of attention-deficit hyperactivity disorder
06/23/2005WO2005025496A3 Aliphatic pyrazinoylguanidine sodium channel blockers
06/23/2005WO2005016258A3 Treatment of age-related macular degeneration
06/23/2005WO2005009358A3 Conformationally constrained parathyroid hormone (pth) analogs
06/23/2005WO2005007104A3 Novel compositions, pharmaceutical compositions, and methods for the treatment and prevention of heart disease
06/23/2005WO2005002505A3 Apolipoprotein c-1 induced apoptosis
06/23/2005WO2005000213A8 Method for treating diseases using hsp90-inhibiting agents in combination with enzyme inhibitors
06/23/2005WO2004100880A3 Controlled release formulation of erythromycin derivatives
06/23/2005WO2004098521A3 Treatment and diagnostics of cancer
06/23/2005WO2004096142A3 Alk protein tyrosine kinase, cells and methods embodying and using same
06/23/2005WO2004087064A3 Compounds and methods for use in treating neoplasia and cancer based upon inhibitors of isoprenylcysteine methyltransferase
06/23/2005WO2004080373A3 Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2)
06/23/2005WO2004069190A3 Combination therapy for treating protein deficiency disorders
06/23/2005WO2004039327A8 Use of equol for treating androgen mediated diseases
06/23/2005US20050137592 Vessel sealing instrument
1 ... 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 ... 295